Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$415.62M+10.5%$376.07M+18.3%$317.93M+20.7%$263.47M+23.8%$212.82M+8.3%
$37.65M+2.6%$36.7M+15.0%$31.91M+11.1%$28.73M+16.3%$24.7M+29.1%
$377.98M+11.4%$339.38M+18.7%$286.02M+21.8%$234.74M+24.8%$188.12M+6.0%
90.9%+0.7pp90.2%+0.3pp90%+0.9pp89.1%+0.7pp88.4%-1.9pp
$90.14M+17.0%$77.05M+8.4%$71.08M+0.1%$70.98M+0.2%$70.82M-7.3%
$284.63M+3.7%$274.55M+8.4%$253.18M+1.4%$249.6M+4.6%$238.6M+4.0%
$412.41M+6.2%$388.3M+9.0%$356.18M+2.0%$349.3M+4.5%$334.12M+2.8%
-$38.25M+55.4%-$85.84M+29.2%-$121.3M+5.5%
$13.47M+11.5%$12.08M-17.4%$14.63M-19.7%$18.22M-19.7%$22.67M-16.6%
$985K-15.9%$1.17M+14.4%$1.02M+8.5%$944K+56.8%$602K-7.0%
-$44.32M+52.5%-$93.27M+28.1%-$129.72M+7.4%
-$0.35+52.7%-$0.74+28.2%-$1.03+10.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Arcutis Biotherapeutics, Inc.'s profit margins?
Gross margin is 90.9% and operating margin is -12.0%, with a -13.9% net margin.
Where does Arcutis Biotherapeutics, Inc.'s income statement data come from?
Every line is extracted from Arcutis Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.